The following is a summary of the Theralase Technologies Inc. (TLTFF) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Theralase Technologies reported a 6% YoY decrease in sales to $1.07 million.

• Cost of sales was $510,000 or 47% of sales, allowing for a gross margin of $462,000 or 53% of sales.

• Selling expenses saw a decrease of 7% attributed to reductions in sales salaries and advertising.

• Administrative expenses marked a 48% YoY rise due to increased costs towards stock-based compensation, investor relations, general and admin expenses, and director and advisory fees.

• A marked decrease of 30% in R&D costs due to less expenditure on their bladder cancer clinical study.

• The company experienced a net loss of $4.57 million, marking a 13% YoY decrease.

• The completion of four non-brokered private placements led to increased capital in 2023 and 2024.

Business Progress:

• The company plans to complete accrual for its Phase II bladder cancer study by the end of 2024.

• Concurrently developing a therapy for bladder cancer, showing promising clinical trials with high efficacy and safety rates.

• A pre-BTD submission is expected to submit to FDA in Q2 of 2024.

• Engagement with various pharmaceutical organizations for potential partnerships is underway.

• Preparation for a Phase 1b clinical study for brain and lung cancer is in progress, pending regulatory approval.

• Current collaboration with the University of Manitoba and National Microbiology Laboratory towards developing a COVID-19 vaccine, with results expected by Q2 or Q3, 2024.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.